Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Ocular Therapeutix (0OT) AI Stock Analysis

DE:0OT

Ocular Therapeutix

(Frankfurt:0OT)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong Gross MarginsConsistently high gross margins indicate that Ocular Therapeutix’s products and technology can generate substantial value after direct costs. This provides a solid economic foundation for future scale, although operating discipline and sufficient revenue growth are still needed to convert gross profit into sustainable earnings.
Negative Factors
Worsening Operating LossesWorsening operating losses show that the company is not yet converting its strong gross margins into sustainable earnings. Continued losses can constrain investment choices, increase dependence on external financing, and make it harder to fund pipeline development without shareholder dilution.

Ocular Therapeutix (0OT) vs. iShares MSCI Germany ETF (EWG)

-40%-20%0%20%40%60%DE:0OT-29.94%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 1.53B
Dividend Yield
―
Average Volume (3M)
1,185
Price to Earnings (P/E)
-4.9
Beta (1Y)
0.56
Revenue Growth
-14.32%
EPS Growth
-3.11%
Country
Germany
Employees
325
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Ocular Therapeutix Business Overview & Revenue Model

Company Description

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range...

Ocular Therapeutix Earnings Call Summary

Earnings Call Date:May 04, 2026(Q1-2026)|% Change Since:-20.13%|Next Earnings Date:Nov 08, 2026
Earnings Call SentimentPositive

The call conveyed a strongly positive clinical narrative: a landmark superiority result (p=0.0006), clear durability and anatomic benefits, an encouraging safety profile, robust enrollment and accelerated timelines for SOL-R, initiation of a long-term extension (SOL-X), and a solid cash position. The primary negatives were regulatory/timing uncertainty, the explicit note that cash runway excludes full commercialization costs, and limited disclosure of some granular metrics. On balance, the highlights substantially outweigh the lowlights.

Positive Updates

First-in-Class Superiority in Phase III (SOL-1)
AXPAXLI (SOL-1) demonstrated statistical superiority versus an approved anti-VEGF in wet AMD with a primary endpoint p-value of 0.0006, marking the first novel investigational therapy to achieve this in a Phase III wet AMD trial.

Negative Updates

Regulatory and Timing Uncertainty
Although management reports productive, formal discussions with the FDA, specific meeting details and exact filing/timeline commitments were not disclosed; reliance on a single‑trial submission remains subject to ongoing FDA dialogue and potential changes in agency expectations.

Company Guidance

Management guided that it remains on track to pursue an NDA relying on SOL‑1 week‑52 data (primary endpoint p=0.0006), leveraging a 505(b)(2) pathway and an existing SPA while continuing formal discussions with the FDA; SOL‑R completed randomization at 631 subjects (vs a 555 target) in Dec 2025 with top‑line data accelerated to Q1 2027, and SOL‑X has been initiated to give patients who complete 2 years in SOL‑1/SOL‑R an additional 3 years of AXPAXLI for a total of 5 years of follow‑up. They emphasized SOL‑1 efficacy and durability metrics — ~75% rescue‑free at ~9 months, ~66% maintaining vision through 12 months, ~56% maintaining CST within 30 microns after a single injection, ~5–6 months delayed time to >30/75 µm fluid increases versus aflibercept, and a 6‑month delay in reaching the aflibercept rescue rate (week 28 vs week 52) — plus a reassuring safety profile with no treatment‑related serious ocular/systemic AEs reported, and a strong financial position with approximately $667M cash as of March 31, 2026, providing runway into 2028 (excluding full commercialization spend); an Investor Day is scheduled for June 17, 2026.

Ocular Therapeutix Risk Analysis

Ocular Therapeutix disclosed 54 risk factors in its most recent earnings report. Ocular Therapeutix reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk
1.Item 5. Other Information. Director and Officer Trading ArrangementsQ2, 2026

Ocular Therapeutix Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:0OT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TARSTARS78Outperform$3.69B-68.67-13.53%―105.17%53.58%
AURAAURA53Neutral$636.75M-3.45-73.18%――9.05%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
OCSOCS45Neutral$509.91M-4.87-42.92%――34.21%
EYPTEYPT39Underperform$30.04M-0.09-135.81%―-94.63%-39.78%
RGNXRGNX34Underperform$475.30M-1.90-220.07%―12.00%-9.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:0OTEYPTRGNXTARSOCSAURADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:0OT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:0OTOcular Therapeutix Inc6.35-3.53-35.75%
EYPTEyepoint Pharma0.35-12.10-97.20%
RGNXRegenXBio Inc.7.20-4.79-39.95%
TARSTarsus Pharmaceuticals, Inc.74.855.067.25%
OCSOculis Holding Ag8.26-11.22-57.60%
AURAAura Biosciences Inc6.140.101.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.